国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

丹麥Biomonitor
Biomonitor A/S 是一家位于丹麥的未上市公司，創(chuàng)立于2003年，由丹麥 Sunstone Capital 提供資助。該公司是開發(fā)創(chuàng)新型可靠檢測技術(shù)并將這些測試融入大型全方位患者監(jiān)測計劃的領(lǐng)先公司之一。除了面向多發(fā)性硬化患者的監(jiān)測計劃之外，該公司還為接受抗 TNF 藥物治療的患者提供實驗室測試服務(wù)（藥物的循環(huán)水平和抗藥抗體的監(jiān)測），并作為一家專業(yè)化合同研究組織 (CRO) 為藥物和生物技術(shù)行業(yè)的多種生物藥物開發(fā)計劃提供支持。Biomonitor Limited 是 Biomonitor A/S 的全資子公司，位于愛爾蘭戈爾韋，是一家獲得 ISO 認(rèn)證的生產(chǎn)機構(gòu)。

Biomonitor A/S is a privately held Danish company founded in 2003 and funded by Sunstone Capital, Denmark. The company is among the leaders in developing innovative, reliable assay technologies and incorporating these tests into large and comprehensive patient-monitoring programs. In addition to monitoring programs for MS patients, the company offers laboratory-testing services for patients on anti-TNF drug therapy (both circulating levels of drug and detection of ADAs, and, as a specialized CRO, supports the pharma and biotech industry in their drug-development programs for many classes of biological drugs. Biomonitor Limited is Biomonitor A/S’s wholly owned subsidiary located in Galway, Ireland and is an ISO-certified manufacturing facility.

Biomonitor was founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen and has since its inception grown rapidly.

The foundation of the company is based on Professor Klaus Bendtzen’s many years of experience from his research work at the Copenhagen University Hospital on inflammation and immunology. Prof. Klaus Bendtzen discovered through his work how some patients form antibodies against those proteins and peptides that are used in biopharmaceutical products for the treatment of a range of chronic diseases. Antibodies can neutralize the biopharmaceuticals that patients receive and patients with antibodies thereby do not or only marginally benefit from such treatments so it became crucial to develop methods to monitor biopharmaceuticals.

Biopharmaceutical treatments are very costly and potentially dangerous. Consequently, it makes good sense to monitor patients so that the drugs can be tailored to the individual patient and so that physicians early on can deal with patients who develop antibodies. By doing this, patients, society and insurance companies can save tremendous amount of resources and the patient can be relieved from a treatment that does not work as designed. Most biopharmaceutical treatments are relatively new, and Biomonitor is one of the leading companies in the field, which monitors these therapies.

In November 2008 Biomonitor acquired Neutekbio Ltd. With its proprietary platform of products based on reporter gene technology and developed cell-based assays and kits called iLite?, Neutekbio Ltd. complements Biomonitor’s offerings in assays for patient monitoring and biopharmaceutical drug development programs. The discovery research is performed through a collaborative research and development agreement with the Laboratory of Viral Oncology (The Centre National Recherché Scientifique) in the Institute Andre Lwoff, Villejuif, France. These research programs have been carried out under the direction of Dr. Michael Tovey, an international leader in cytokine research and interferon therapy.